Man Group plc Decreases Stock Position in Haemonetics Co. (NYSE:HAE)

Man Group plc trimmed its holdings in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 87.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 3,098 shares of the medical instruments supplier's stock after selling 21,511 shares during the period. Man Group plc's holdings in Haemonetics were worth $242,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of HAE. Janney Montgomery Scott LLC purchased a new position in Haemonetics in the 4th quarter worth about $402,000. KBC Group NV raised its stake in Haemonetics by 54.6% during the 4th quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier's stock worth $157,000 after acquiring an additional 712 shares during the period. Pacer Advisors Inc. lifted its holdings in Haemonetics by 36.1% during the fourth quarter. Pacer Advisors Inc. now owns 10,104 shares of the medical instruments supplier's stock valued at $789,000 after purchasing an additional 2,680 shares in the last quarter. Boston Trust Walden Corp lifted its holdings in Haemonetics by 13.1% during the fourth quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier's stock valued at $71,500,000 after purchasing an additional 106,114 shares in the last quarter. Finally, Empowered Funds LLC bought a new position in shares of Haemonetics in the fourth quarter worth approximately $319,000. Institutional investors own 99.67% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on HAE. Wall Street Zen cut shares of Haemonetics from a "buy" rating to a "hold" rating in a research note on Tuesday, May 13th. JMP Securities reiterated a "market outperform" rating and issued a $100.00 target price on shares of Haemonetics in a research report on Tuesday, May 20th. Needham & Company LLC cut their price target on Haemonetics from $104.00 to $84.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Barrington Research lowered their target price on Haemonetics from $108.00 to $95.00 and set an "outperform" rating for the company in a research report on Friday, February 7th. Finally, Raymond James reissued a "strong-buy" rating and issued a $105.00 target price (down from $115.00) on shares of Haemonetics in a report on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $97.89.

Haemonetics Trading Up 0.4%

HAE stock traded up $0.24 during mid-day trading on Thursday, reaching $67.85. The company had a trading volume of 674,860 shares, compared to its average volume of 680,392. Haemonetics Co. has a 12 month low of $55.30 and a 12 month high of $94.99. The company has a market capitalization of $3.26 billion, a PE ratio of 26.71, a price-to-earnings-growth ratio of 1.11 and a beta of 0.32. The firm has a 50 day moving average of $63.29 and a 200 day moving average of $70.70. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55.

Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.22 by $0.02. The firm had revenue of $330.60 million for the quarter, compared to the consensus estimate of $329.38 million. Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. The company's quarterly revenue was down 3.5% on a year-over-year basis. During the same period last year, the firm earned $0.90 earnings per share. On average, equities analysts predict that Haemonetics Co. will post 4.55 earnings per share for the current fiscal year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.